300003:SZSELepu Medical Technology (Beijing) Co., Ltd. Class A Analysis
Data as of 2026-08-29 - not real-time
CN¥12.06
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Lepu Medical Technology (Beijing) Co., Ltd. is priced at ¥12.06, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has lost 4.1%. With RSI at 43.1 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at ¥11.60 and resistance at ¥13.38.
Valuation screens as undervalued: a P/E of 28.7 sits in line with the sector average of 30.5. Sell-side targets cluster 52.9% above the current quote. Revenue is contracting at 5.6% on a 12.2% profit margin. The 2.70% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 39.4%, a beta of 0.15 and a maximum drawdown of 44.5%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
Valuation screens as undervalued: a P/E of 28.7 sits in line with the sector average of 30.5. Sell-side targets cluster 52.9% above the current quote. Revenue is contracting at 5.6% on a 12.2% profit margin. The 2.70% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 39.4%, a beta of 0.15 and a maximum drawdown of 44.5%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 15.19
- MACD momentum is negative
- Maximum drawdown of 44.5%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 28.7 versus sector average of 30.5
- Trading below the 200-day average of 15.19
- Analyst targets imply +52.9% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 28.7 versus sector average of 30.5
- Analyst targets imply +52.9% versus the current price
- Revenue contracting at -5.6%
Key Metrics & Analysis
Financial Health
Revenue Growth-5.60%
Profit Margin12.18%
P/E Ratio28.7
ROE4.40%
ROA2.34%
Debt/Equity35.58
P/B Ratio1.4
Op. Cash FlowCN¥1.5B
Free Cash FlowCN¥514.4M
Industry P/E30.5
Technical Analysis
TrendNeutral
RSI43.1
SupportCN¥11.60
ResistanceCN¥13.38
MA 20CN¥12.61
MA 50CN¥12.54
MA 200CN¥15.19
MACDBearish
VolumeDecreasing
Fear & Greed Index95.66
Valuation
Fair ValueCN¥2.53
Target PriceCN¥18.44
Upside/Downside52.86%
GradeUndervalued
TypeValue
Dividend Yield2.70%
Risk Assessment
Beta0.15
Volatility39.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.